Meanwhile, the cardiovascular field has introduced new anticoagulants (e.g., DOACs), PCSK9 inhibitors, and SGLT2 inhibitors, alongside updated guidelines for hypertension and heart failure, such as stricter blood pressure targets and recommendations for novel therapies. The gene discussed is PCSK9; the disease is hypertensive disorder.